This week, Abbott announced its plans to acquire Bigfoot Biomedical — a startup selling a “smart” insulin pen cap, which collects data from a user’s CGM to help them calculate the right dose. Most analysts were unsurprised to hear of the acquisition given that the two companies have been collaborating for more than six years, but they said the deal reinforces the steady pace of digital innovation in the diabetes care space.

Social media should play a bigger part in public health crisis planning, according to a recent analysis. The analysis explored the crucial role that Twitter and other social media platforms played when the app for Abbott’s FreeStyle Libre system crashed earlier this month in the U.K.

In an interview at the J.P. Morgan Healthcare Conference in San Francisco earlier this week, the CEO of Dexcom relayed a strong desire to sell CGM systems directly to the consumers with possible pilots this year.

Medical device maker Dexcom is partnering with Livongo such that users of Livongo that have diabetes and use Dexcom’s continuous glucose monitoring system can sync their data on the Livongo platform.

On the day that an FDA official exhorts industry to develop interoperable diabetes devices, Medtronic announces that it is teaming up with a nonprofit group to do just that.

Medtronic had previously betted on higher adoption of its insulin pumps tethering the use of continuous glucose monitors to those pumps but has recently returned to the standalone CGM market with the launch of its Guardian Connect device in the U.S. Should Dexcom and Abbott worry?